Orexigen Insists Revised Contrave Data Should Not Affect Review Timeline
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Although Orexigen Therapeutics needed to correct data included in the NDA for its Contrave obesity drug, the company appears to have weathered some shareholder concern and may be on an unchanged timeline for FDA consideration and approval of its application
You may also be interested in...
Arena Gets Financing Boost, Lorcaserin Advisory Committee Date
Deerfield takes a $35.5 million equity stake, but finding a commercialization partner is still Arena's focus as it prepares for the September 16 panel review of its obesity drug.
Arena Gets Financing Boost, Lorcaserin Advisory Committee Date
Deerfield takes a $35.5 million equity stake, but finding a commercialization partner is still Arena's focus as it prepares for the September 16 panel review of its obesity drug.
Orexigen Empatic That Results for Second Obesity Drug Will Help Lure A Partner
Specter of birth defect risk could limit use of its Empatic diet pill and late-stage rival Qnexa, from Vivus, in younger women.